Abstract: Besides being Canada’s particle accelerator center with an emphasis on nuclear, particle, and accelerator physics, TRIUMF has a long history of medical isotope production and radiotherapy. Cancer treatment with different particles has been a long-standing commitment at TRIUMF, first with pion therapy and then with proton therapy, for many years operating Canada’s only proton therapy facility. To improve treatment with protons, we have established new beam-shaping methodologies by employing additive manufacturing, are investigating new detectors for proton dosimetry, and are researching in vivo range verification in real time. In addition, we are investigating using alpha and Auger emitters for targeted radioisotope therapy and are building a facility at our new ARIEL accelerator to take advantage of its large flux to investigate treatment with photons in less than a second in Flash therapy.

Bio: Cornelia Hoehr received her Ph.D. in physics from Heidelberg University in Germany and the Max-Plank institute for Nuclear Physics in Heidelberg. After a postdoctoral research term at Argonne, she moved to TRIUMF as a postdoctoral researcher, and subsequently took on roles in operation and facilities in isotope production and proton therapy. She is currently the Deputy Associate Laboratory Director – Life Sciences at TRIUMF. Her research interests focus on medical isotope production and proton therapy.